Clinical, electrocardiographic, and echocardiographic parameters associated with the development of pacing and implantable cardioverter-defibrillator indication in patients with transthyretin amyloid cardiomyopathy

Kawahara, Y; Kanazawa, H; Takashio, S; Tsuruta, Y; Sumi, H; Kiyama, T; Kaneko, S; Ito, M; Hoshiyama, T; Hirakawa, K; Ishii, M; Tabata, N; Yamanaga, K; Fujisue, K; Hanatani, S; Sueta, D; Arima, Y; Araki, S; Usuku, H; Nakamura, T; Yamamoto, E; Soejima, H; Matsushita, K; Kawano, H; Tsujita, K

doi:10.1093/europace/euad105

Heart failure & cardiomyopathies

Clinical, electrocardiographic, and echocardiographic parameters associated with the development of pacing and implantable cardioverter-defibrillator indication in patients with transthyretin amyloid cardiomyopathy

EuropacePublished 26 Apr 2023Retrospective cohort study

Read the original article ↗PubMed

Cite

Authors' conclusion

According to our retrospective single-center observational study, prophylactic PDI did not require first-degree AV block in both ATTRwt-CM and ATTRv-CM patients, and prophylactic ICD implantation was also controversial in both ATTR-CM.

Study context

Population: ATTRwt-CM and ATTRv-CM patients without a pacing device or pacing device implantation (PDI) indication at diagnosis114 ATTRwt-CM, 50 ATTRv-CM

Exposure: Conduction disturbance at diagnosis vs normal atrioventricular (AV) conduction
Outcome: Future pacing device implantation (PDI)

Methodological detailssingle-centre, consecutive patients

Single-centre
Consecutive patients

Main finding

As reported in the abstract

Incidence of subsequent PDI by conduction disturbance

Bifascicular block · ATTRwt-CM: HR 13.70; P = 0.019
Bifascicular block · ATTRv-CM: HR 12.94; P = 0.002
First-degree AV block · ATTRwt-CM: HR 2.14; P = 0.511
First-degree AV block · ATTRv-CM: HR 1.57; P = 0.701

Observational data: associations, not effects.

Further findings

Outcome	ATTRwt-CM	ATTRv-CM
Appropriate ICD therapy (anti-tachycardia pacing or shock) in ICD recipients	2 of 16	1 of 3

Appropriate implantable cardioverter-defibrillator (ICD) therapy (anti-tachycardia pacing or shock) in ICD recipients: 19 patients with ICD
Appropriate ICD therapy (anti-tachycardia pacing or shock) in ICD recipients: number of intervals to detect for VT of 16-32

Reference

Authors: Kawahara Y, Kanazawa H, Takashio S, Tsuruta Y, Sumi H, Kiyama T, et al.
All 25 authors
Kawahara Y, Kanazawa H, Takashio S, Tsuruta Y, Sumi H, Kiyama T, Kaneko S, Ito M, Hoshiyama T, Hirakawa K, Ishii M, Tabata N, Yamanaga K, Fujisue K, Hanatani S, Sueta D, Arima Y, Araki S, Usuku H, Nakamura T, Yamamoto E, Soejima H, Matsushita K, Kawano H, Tsujita K
Journal: EP Europace
Published: 26 Apr 2023
DOI: 10.1093/europace/euad105
PubMed: 37099643

Topic: Heart failure & cardiomyopathies
Also indexed: Arrhythmias & electrophysiology

Exposure

Conduction disturbance at diagnosis (bifascicular block, first-degree AV block) vs normal AV conduction

Key notes

ATTRwt-CM: PR-interval ≥220 msec, interventricular septum (IVS) thickness ≥16.9 mm and bifascicular block significantly associated with future PDI
ATTRv-CM: brain natriuretic peptide ≥35.7 pg/mL, IVS thickness ≥11.3 mm and bifascicular block significantly associated with future PDI

Original publication

Clinical, electrocardiographic, and echocardiographic parameters associated with the development of pacing and implantable cardioverter-defibrillator indication in patients with transthyretin amyloid cardiomyopathy. Europace. Published 26 April 2023. doi:10.1093/europace/euad105

Read the original article ↗

Composed by AI from the published abstract and checked against it. How Briefs are made →